Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This study found that Janus kinase inhibitors were effective in inducing clinical and biochemical remission in patients with Ulcerative Colitis while exhibiting an expected safety profile, though 30% discontinued treatment due to adverse events or lack of efficacy.

This study reported a 74% overall response rate for a new combination chemotherapy of mitoxantrone, etoposide, and prednisolone in patients with relapsed or refractory Hodgkin's disease or non-Hodgkin's lymphoma.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

This case report describes a patient who developed PRIDE syndrome-associated skin issues, including a pruritic papulopustular rash and alopecia, after starting treatment with the EGFR inhibitor erlotinib.

In this case study, a 39-year-old Japanese woman with severe alopecia areata demonstrated complete hair regrowth after one year using a combination of 0.5% delgocitinib ointment and excimer laser, suggesting potential efficacy and safety compared to conventional treatments.

The authors report that a 62-year-old woman with invasive conjunctival squamous cell carcinoma experienced complete remission two years after combining cemiplimab, retinoic acid, and IFNα-2b treatments, highlighting potential utility despite limited availability of IFNα-2b.

In this study, the novel isoprenylcysteine analog SIG-1451 was shown to inhibit pro-inflammatory cytokine release in various cell-based assays relevant to allergic dermatitis, acting on targets such as IL-4 and IL-6 with potential anti-inflammatory benefits.

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

This review evaluates the efficacy and safety of enteral nutrition for maintaining remission in quiescent Crohn's disease but finds the evidence inconclusive and calls for further research.

This study found that oral baricitinib was more effective than methotrexate in treating severe alopecia areata, with significant improvements in SALT scores over six months.

This paper provides a comprehensive list of drugs including Ethamolin, Placidyl, Trecator-SC, Zarontin, Peganone, Didronel, and Lodine, detailing their indications, potential interactions, and reported adverse skin reactions, but it presents no new research findings.

Deuruxolitinib is generally safe for treating alopecia areata.

This study found that wedelolactone from Eclipta prostrata L. significantly reduced lung inflammation and fibrosis in mice with bleomycin-induced pulmonary fibrosis, suggesting potential therapeutic benefits through AMPK activation.

This study found that transethosomal gel loaded with propranolol hydrochloride prolonged drug release and increased peak plasma concentration compared to an oral tablet, suggesting a promising alternative for delivery.

This announcement discusses the recent FDA approval of baricitinib for treating severe alopecia areata in adults and reports no new clinical results.

This study found that the antiviral drug daclatasvir significantly improved fibrosis and quality of life in a mouse model of recessive dystrophic epidermolysis bullosa, suggesting potential for treating this and other fibrotic diseases.

This article discusses systemic lupus erythematosus, covering its clinical features, treatments, and the recent FDA approval of belimumab, but does not present new clinical results.

In this study, researchers highlighted that emulgels, a combination of emulsions and gels, offer a novel topical delivery method for hydrophobic drugs, possessing attributes such as easy spreadability and bio-friendliness, making them suitable for conditions like acne, fungal infections, and psoriasis.

Certain factors like being female, having high cholesterol, using Medicaid, and previous non-biologic treatments increase the risk of multiple biologic failures in psoriasis patients.

This study identified a novel splice-site variant of the LAMB3 gene that may cause junctional epidermolysis bullosa, suggesting gene sequencing is essential for accurate diagnosis.

A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.

In this study, baricitinib improved the resolution of arthritis or rash in patients with systemic lupus erythematosus, but outcomes for skin involvement like alopecia were not reported.

This study reported that dupilumab, an FDA-approved biologic, is a safe and effective first-line systemic treatment for children with moderate-to-severe atopic dermatitis, showing sustained skin improvement and itch reduction, with injection site reactions and conjunctivitis as potential side effects.

In this case series, dual-targeted therapy was observed to provide promising clinical responses in refractory inflammatory bowel disease, with 88.23% to 100% response rates across 9 months and an endoscopic response in 88.89% of evaluated patients, though some adverse events occurred.

This study reports no known changes in hair pigmentation associated with brentuximab vedotin, despite its various other documented adverse effects.